Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B
Introduction: The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alon...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Electronic Physician
2016-06-01
|
| Series: | Electronic Physician |
| Subjects: | |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965195/ |
| _version_ | 1818541526773399552 |
|---|---|
| author | Mostafa Mahabadi Seyed Moayed Alavian Mehdi Norouzi Hossein Keyvani Mahmood Mahmoudi Seyed Mohammad Jazayeri |
| author_facet | Mostafa Mahabadi Seyed Moayed Alavian Mehdi Norouzi Hossein Keyvani Mahmood Mahmoudi Seyed Mohammad Jazayeri |
| author_sort | Mostafa Mahabadi |
| collection | DOAJ |
| description | Introduction: The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show
incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination
therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alone in maintaining
virological, biochemical and histological responses and 2) to investigate the patterns of mutations in the reverse
transcriptase and surface proteins of HBV with LAM and/or ADF-resistant in partially-responded chronic
hepatitis B (CHB) patients.
Methods: The study group consisted of 186 chronic HBV carriers who were admitted to the Tehran Hepatitis
Network from 2010 to 2013. We retrospectively selected 86 patients who partially responded to different
nucleoside analogue regimens. After 48 weeks of therapy, five groups of patients were defined including eight
Lamivudine (LAM) Group (I), 30 Adefovir (ADV) Group (II), 16 ADV add on LAM Group (III), 32
ADV+LAM Group (IV), and 100 controls (no therapy). Reverse transcriptase (RT) and surface genes were
amplified and sequenced for mutational analysis.
Results: All groups showed differences between mean values for age, gender, alanine transaminase (ALT),
aspartate transaminase (AST), and HBV DNA levels groups showed significant differences than other groups (p
< 0.05). The mutation frequencies for groups were I (1.7%), II (1.39%), III (2.28%), IV (2.0%), and V (0.38%).
T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all
groups with different frequencies. Four new, unreported mutations were found.
Conclusion: Those patients who failed to respond in the first 48 weeks, whether they were receiving mono or
combination therapy, should be tested genotypically, for the early modification of treatment. |
| first_indexed | 2024-12-11T22:10:26Z |
| format | Article |
| id | doaj.art-d9e4432842854f039abbc2f7a778682d |
| institution | Directory Open Access Journal |
| issn | 2008-5842 2008-5842 |
| language | English |
| last_indexed | 2024-12-11T22:10:26Z |
| publishDate | 2016-06-01 |
| publisher | Electronic Physician |
| record_format | Article |
| series | Electronic Physician |
| spelling | doaj.art-d9e4432842854f039abbc2f7a778682d2022-12-22T00:48:49ZengElectronic PhysicianElectronic Physician2008-58422008-58422016-06-01862466247410.19082/2466Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis BMostafa MahabadiSeyed Moayed AlavianMehdi NorouziHossein KeyvaniMahmood MahmoudiSeyed Mohammad JazayeriIntroduction: The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alone in maintaining virological, biochemical and histological responses and 2) to investigate the patterns of mutations in the reverse transcriptase and surface proteins of HBV with LAM and/or ADF-resistant in partially-responded chronic hepatitis B (CHB) patients. Methods: The study group consisted of 186 chronic HBV carriers who were admitted to the Tehran Hepatitis Network from 2010 to 2013. We retrospectively selected 86 patients who partially responded to different nucleoside analogue regimens. After 48 weeks of therapy, five groups of patients were defined including eight Lamivudine (LAM) Group (I), 30 Adefovir (ADV) Group (II), 16 ADV add on LAM Group (III), 32 ADV+LAM Group (IV), and 100 controls (no therapy). Reverse transcriptase (RT) and surface genes were amplified and sequenced for mutational analysis. Results: All groups showed differences between mean values for age, gender, alanine transaminase (ALT), aspartate transaminase (AST), and HBV DNA levels groups showed significant differences than other groups (p < 0.05). The mutation frequencies for groups were I (1.7%), II (1.39%), III (2.28%), IV (2.0%), and V (0.38%). T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies. Four new, unreported mutations were found. Conclusion: Those patients who failed to respond in the first 48 weeks, whether they were receiving mono or combination therapy, should be tested genotypically, for the early modification of treatment.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965195/nucleoside analogues (NA)partial responsedrug resistant variantshepatitis |
| spellingShingle | Mostafa Mahabadi Seyed Moayed Alavian Mehdi Norouzi Hossein Keyvani Mahmood Mahmoudi Seyed Mohammad Jazayeri Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B Electronic Physician nucleoside analogues (NA) partial response drug resistant variants hepatitis |
| title | Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B |
| title_full | Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B |
| title_fullStr | Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B |
| title_full_unstemmed | Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B |
| title_short | Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B |
| title_sort | mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype d chronic hepatitis b |
| topic | nucleoside analogues (NA) partial response drug resistant variants hepatitis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965195/ |
| work_keys_str_mv | AT mostafamahabadi mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb AT seyedmoayedalavian mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb AT mehdinorouzi mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb AT hosseinkeyvani mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb AT mahmoodmahmoudi mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb AT seyedmohammadjazayeri mutationalanalysisofreversetranscriptaseandsurfaceproteinsofpatientswithpartialvirologicalresponseduringmonoandcombinationantiviraltherapiesingenotypedchronichepatitisb |